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Autoimmune hemolytic anemia (AIHA) is a greatly heterogeneous disease due to
autoantibodies directed against erythrocytes, with or without complement activation.
The clinical picture ranges frommild/compensated to life-threatening anemia, depending
on the antibody’s thermal amplitude, isotype and ability to fix complement, as well as
on bone marrow compensation. Since few years ago, steroids, immunesuppressants
and splenectomy have been the mainstay of treatment. More recently, several target
therapies are increasingly used in the clinical practice or are under development
in clinical trials. This has led to the accumulation of refractory/relapsed cases that
often represent a clinical challenge. Moreover, the availability of several drugs acting
on the different pathophysiologic mechanisms of the disease pinpoints the need to
harness therapy. In particular, it is advisable to define the best choice, sequence
and/or combination of drugs during the different phases of the disease. In particular
relapsed/refractory cases may resemble pre-myelodysplastic or bone marrow failure
syndromes, suggesting a careful use of immunosuppressants, and vice versa advising
bone marrow immunomodulating/stimulating agents. A peculiar setting is AIHA after
autologous and allogeneic hematopoietic stem cell transplantation, which is increasingly
reported. These cases are generally severe and refractory to standard therapy, and have
high mortality. AIHAs may be primary/idiopathic or secondary to infections, autoimmune
diseases, malignancies, particularly lymphoproliferative disorders, and drugs, further
complicating their clinical picture and management. Regarding new drugs, the false
positivity of the Coombs test (direct antiglobulin test, DAT) following daratumumab adds
to the list of difficult diagnosis, together with the passenger lymphocyte syndrome
after solid organ transplants. Diagnosis of DAT-negative AIHAs and evaluation of
disease-related risk factors for relapse and mortality, notwithstanding improvement in
diagnostic approach, are still an unmet need. Finally, AIHA is increasingly described
following therapy of solid cancers with inhibitors of immune checkpoint molecules. On the
whole, the double-edged sword of new pathogenetic insights and therapies has changed
the landscape of AIHA, both providing enthusiastic knowledge and complicating the
clinical management of this disease.
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INTRODUCTION
Autoimmune hemolytic anemia (AIHA) has always been
considered the simplest and most scholastic example of
antibody-mediated autoimmune disease. As a matter of
fact, autoantibodies (Ab) directed against erythrocytes,
with or without complement (C) activation, are the main
pathogenic mechanism of the disease (1). Clinically, it has
long been considered a trouble-free disease, easy to treat,
and with low clinical impact, compared with malignant
hematologic conditions. This approach is quite similar to
that of immune thrombocytopenia, which has been defined
the “hematology’s Cosette from Les Misérables.” More
recently, AIHA has been identified as a greatly heterogeneous
disease, due to several immunological mechanisms involved
beyond antibodies, complement and antibody-dependent
cell-mediated cytotoxicity (ADCC). Accumulating evidence
demonstrates reduced CD4+ T-regs, imbalance of T-helper
1/2 cytokines, increased activity of cytotoxic CD8+ T
lymphocytes, natural killer cells, and activated macrophages.
More importantly, attention has grown on the pivotal role
of bone marrow compensation, and on bone marrow
characteristics that may reveal dyserythropoiesis, fibrosis,
and clonal lymphoproliferation (1–4). Previously, steroids,
immunesuppressants, and splenectomy were the mainstay of
AIHA treatment (5–8). More recently, several new targeted
therapies are increasingly used in the clinical practice or
under development in clinical trials (7, 9). Along with new
therapeutic options for patients, this growing armamentarium
has complicated the clinical management of AIHA and
increased the number of relapsed/refractory cases. Therefore,
harnessing treatment and defining a risk-adapted therapy
is an emerging unmet need. A peculiar setting is AIHA
after autologous and allogeneic hematopoietic stem cell
transplantation (HSCT), as well as cases described during
therapy with immune checkpoint inhibitors for solid cancers
(10). Finally, AIHAs may be associated with several conditions
(lymphoproliferative, autoimmune and infectious diseases,
immunodeficiencies, solid tumors, transplants, and drugs)
where the several immunologic mechanisms are unpredictably
involved (7, 11). The recent availability of next generation
sequencing has improved the diagnosis of the several associated
conditions, but at the same time has extended the proportion
of “secondary” vs. “primary” AIHAs (4, 12). All these new
insights in the pathogenesis of the disease and treatment
opportunities have undoubtedly changed the landscape
of AIHA.
In this review we will describe new diagnostic tools,
clinical characteristics and therapeutic options of AIHA,
focusing on relapsed/refractory cases, secondary forms,
and AIHAs associated with HSCT or therapy with
immune checkpoint inhibitors (CPIs). Moreover, we
will approach the identification of risk factors for the
development, clinical severity, response to therapy, and
outcome of AIHA in order to start the basis for a
risk-adapted therapy.
CLINICAL CHARACTERISTICS AND
CLASSIFICATION OF AIHA
The gold standard for the diagnosis of AIHA is the Coombs test
or direct antiglobulin test (DAT) that enables the classification of
the disease according to the isotype and thermal characteristics
of the autoantibody. Warm AIHA (wAIHA), the most common
type (60–70% of cases) is typically DAT positive for anti-IgG,
or IgG plus C, while cold forms (cold agglutinin disease, CAD,
20–25%), are due to IgM, and the DAT is positive for C3d.
Among cold AIHAs it is worth considering paroxysmal cold
hemoglobinuria (PCH), usually observed in children and; this
very rare type of AIHA (1–5% of cases) is caused by the Donath-
Landsteiner autoantibody, a bithermic hemolysin able to fix
complement at cold temperatures and to determine RBCs lysis
at 37◦C. Mixed forms show both characteristics of wAIHA and
CAD, with a DAT positive for both IgG and C and high titer cold
agglutinins. Finally, there is a heterogeneous group of atypical
AIHAs that include DAT negative, IgA driven, and warm IgM
types (7, 8, 13). All these forms have a variable degree of anemia,
hemolysis and bone marrow compensation, as shown in Table 1
for Hb and LDH levels, and reticulocyte counts.
Risk Factors for Relapse and Mortality
Given the great clinical heterogeneity of the various AIHA forms,
an effort has been made to identify predictors of outcome,
including complications, response to therapy and death. The
severity of anemia at onset has been identified as the strongest
predictor of relapse, with hazard ratios of 1.61, 1.74, and
1.98, for Hb levels of 8.1–10, 6.1–8, <6 g/dL, respectively
(5, 8). Complement involvement and thermal characteristics
of the autoantibody were also important, with warm IgG+C,
mixed, CAD, and atypical forms more frequently needing
second or further therapy lines. Moreover, the concomitant
presence of immune thrombocytopenia (Evans syndrome) is
associated with a higher risk of relapse and refractoriness to
treatment. Overall, AIHAs other than warm forms, plus Evans
syndrome and Hb<8 g/dL at onset had a 4-fold increased
risk of multiple relapses (8). Moreover, bone marrow features
impact on disease severity since the presence of reticular
fibrosis, dyserithropoiesis, and hypercellularity correlated with
shorter relapse-free survival and lower response rate to
immunosuppressive therapies (3). Regarding fatal outcome, Hb
<6 g/dL at onset, Evans’ syndrome, multi-treatment, acute renal
failure, and infections have been associated with 5-8 fold risk
of increased mortality (8). A case series of 13 very severe
relapsed/refractory primary AIHA reported a mortality of 57%,
despite intensive treatment, including transfusions, steroid boli,
intravenous immunoglobulins, rituximab, erythropoietin, and
plasma-exchange (13). More recently, mortality was 30% in a
series of 44 AIHA admitted to intensive care unit for severe
anemia (14). It is worth remembering that about 15–20% of
AIHAs display thrombotic events, including severe episodes
(pulmonary embolism, stroke, cardiac infarction), which are
generally proportional to active hemolysis (5, 7). Risk factors
for these severe, although not fatal, complications are Hb
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TABLE 1 | Clinical and laboratory characteristics of patients at onset divided according to AIHA serological type.
wAIHA
(n = 225) IgG (n = 158);
IgG +C (n = 67)
CAD (n = 107) Mixed AIHA
(n = 24)
Atypical AIHA
(n = 22)
Hematologic features of primary AIHA patients
Median Age at diagnosis (years, range) 67 (5–94); 65 (21–92) 70 (28–94) 61 (20-86) 45 (25-78)
Hb (g/dL), median (range) 7.3 (2.1–14.1); 6.5
(2.0–11.5)
8.2 (4.0–13.5) 6.4 (4.3–10.7) 6.6 (3.0–10.9)
LDH (ULN), median (range) 1.7 (0.6–26.7); 1.8 (0.8–7.2) 1.4 (0.3–12.2) 1.7 (0.6–9.8) 2 (0.7–18.1)
Ret (×109/L), median (range) 180 (22–644); 143 (53–641) 123 (13–644) 181 (45–576) 195 (29–780)
Inadequate reticulocytosis, n of pts (%) 86 (54); 35 (52) 69 (64) 15 (62) 14 (64)
Hazard risks for AIHA relapse
Hb at onset <6 g/dl HR 1.98 95% CI 1.2–3.2
AIHA type Non wAIHA HR 1.21 95% CI 0.9–1.5
Evans Syndrome Co-presence of ITP HR 1.84 95% CI 1.2–2.7
Hazard risks for AIHA related death
Evans Syndrome Co-presence of ITP HR 8 95% CI 2.5–26
AIHA related complications Acute renal failure HR 6.3 95% CI 1.4–29
Multi-treatment (>4 lines) Infections HR 4.8 95% CI 1.5–15
wAIHA, warm autoimmune hemolytic anemia; CAD, cold agglutinin disease; IgG, DAT positive for IgG; IgG + C, DAT positive IgG + C; LDH (ULN), LDH is expressed as folds of upper
limit of normal.
levels <6 g/dL at onset, increased LDH levels, and previous
splenectomy (8).
Secondary AIHAs
Several conditions represent a risk factor for the development
of AIHA, including lymphoproliferative and autoimmune
diseases, immunodeficiencies, infections, and solid tumors
(Table 2). Concerning lymphoproliferative disorders, CLL
patients show the highest risk with up to 5–10% developing
AIHA, with an onset that may precede the diagnosis of
lymphoproliferative disease (11, 15). The presence of unmutated
IGHV status, sterotyped IGHV frames, and unfavorable
cytogenetics (chromosome 17p and/or 11q deletions) represent
a risk factor for the development of AIHA (4, 15–17). Other
recently identified risk factors were several down-regulated
miRNAs, some of them known to be involved in autoimmune
phenomena (4). Of note, a positive DAT without hemolysis is
frequent in CLL. AIHA prevalence in NHL is 2–3%, with higher
frequencies in some subtypes (13–19% in angioimmunoblastic
T-cell lymphoma and 50% in marginal zone lymphoma)
(7, 11). A particular setting is CAD, which is associated with
an indolent clonal lymphoid infiltrate distinct from other
NHL (2, 6). In this disease recurrent mutations of KMT2D
and CARD11 have been identified in 69 and 31% of cases,
respectively (18). Similar mutations have also been reported
in Kabuki syndrome, a congenital disorder characterized
by malformations, immune-deficiency, and development of
autoimmune diseases (4, 18).
Regarding AIHA in the context of immune dysregulation,
patients with systemic lupus erythematosus develop AIHA in
14% of pediatric cases and 3% of adults (7, 11). A close association
has also been reported with thyroid autoimmune disorders, such
as Hashimoto thyroiditis and Graves’ disease. Several case reports
exist for AIHA association with systemic sclerosis, Sjögren
syndrome (SS), autoimmune liver disorders, and inflammatory
bowel diseases (7, 11). Moreover, various immunodeficiencies
have been identified as predisposing conditions for AIHA,
including common variable immunedeficiency (19), IgA
deficiency, and autoimmune lymphoproliferative syndromes
(ALPS) (20). Interestingly, mutations in genes implicated
in primary immunodeficiencies (TNFRSF6, CTLA4, STAT3,
PIK3CD, CBL, ADAR1, LRBA, RAG1, and KRAS) have been
detected in about half of pediatric patients with AIHA and
ITP (Evans Syndrome, ES); mutated patients showed more
severe disease with higher treatment requirement and fatal
outcome (12). These findings underline the close link between
autoimmunity and immunodeficiency, i.e., a shared condition of
dysregulated immune system.
Genetic Background and Exogenous
Triggers for AIHA Development
Although not specifically involved in the changing landscape of
AIHA, it is worth considering genetic factors and historically
recognized exogenous triggers (4). Several old and recent studies
demonstrated a strong association of AIHA with HLA-B locus,
particularly HLA-B8 and BW6 (21), or a reduced frequency of the
disease in subjects harboring the HLA-DQ6 locus (22) (Table 2).
As regards humoral immune response, various variable regions
of the immunoglobulin heavy and light chains (IGHV and IGKV)
have been associated with AIHA, particularly IGHV4-34, IGHV3,
and IGKV3-20 genes, responsible for I antigen binding, and
mostly represented in CAD (6). Concerning cellular immunity,
autoreactive clonal T- CD8+cells have been reported in about
50% of AIHA cases; moreover, polymorphism of the cytotoxic
T-lymphocyte antigen-4 (CTLA-4) gene and of lymphotoxin-α
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TABLE 2 | Secondary conditions associated with autoimmune hemolytic anemia (AIHA).
Frequency Results
Lymphoproliferative disorders
Chronic lymphoid leukemia and NHL 5–20% Autoimmune cytopenias may frequently complicate chronic lymphoproliferative
disorders and usually correlate with advanced disease and high biologic risk
KMT2D and CARD11 69 and 31% of cAIHA tested Autoreactive B-cells display somatic mutations favoring proliferation
Congenital syndromes and immunodeficiencies
Kabuki syndrome and Hemoglobinopathies 4–6% AIHA and ITP are the most frequent autoimmune complications of Kabuki
Syndrome; DAT positivity is frequent, but clinically overt AIHA is rarer in
thalassemia (particularly beta intermedia, alloimmunized, and transfused pts)
ALPS; CVID; IgA deficiency 2–70% AIHA is the most frequent autoimmune complication together with ITP and ES
Genes involved in PIDs
TNFRSF6, CTLA4, STAT3, PIK3CD, CBL, ADAR1,
LRBA, RAG1, and KRAS
40% of pediatric ES Majority of pediatric ES display somatic mutations found in immunodeficiencies
Autoimmune diseases
SLE, Systemic sclerosis; autoimmune thyroiditis; Sjogren
Syndrome; IBDs; Autoimmune hepatitis/Primary biliary
cirrhosis
1.4–14% AIHA frequency is higher in pediatric than in adult patients with SLE. AIHA may
be rarely associated to systemic sclerosis or Sjogren syndrome, Hashimoto
thyroiditis and Graves’ disease, ulcerative colitis, and autoimmune hepatitis.
Genetic findings
HLA I and II Case series HLA-B8 and BW6 are strongly associated to wAIHA.
IGHV and IGKV region >60% cAIHA Specific IGVH and IGKV regions are related to AIHA development
TCRG and TCRB 50% Pathogenic T-cells are clonally restricted in AIHA
CTLA-4 exon 1 73% CTLA-4 signaling is defective in AIHA, particularly in CLL cases
Cytokine polymorphisms 41% AIHA shows higher frequency of LT-α (+252) AG phenotype
Infections
Parvovirus B19; HCV; HAV; HBV; HIV
Mycoplasma spp.; Tubercolosis; Babesiosis; Brucellosis;
Syphilis; EBV; Respiratory Syncytial Virus
0.02–20% ParvoB19 infection and HCV and its treatment correlate with AIHA development;
case reports of association with AIHA are available for the other infectious
agents.
Drugs
Antibiotics (penicillins, cephalosporins, etc.), cytotoxic
drugs (oxaliplatin, etc.), antidiabetics (metformin),
anti-inflammatory drugs (diclofenac, etc.), neurologic
drugs (α-methyldopa, L-dopa, chlorpromazine, etc.),
cardiologic drugs (procainamide, etc.)
Case reports and reviews Various mechanisms are demonstrated: hapten and drug absorption
mechanisms; Immune/ternary complex mechanisms; autoantibody mechanism;
non-immunologic protein formation; unknown mechanisms.
CLL therapy: fludarabine and Tyrosin kinase inhibitors 6–21% Fludarabine induced AIHA may be avoided by rituximab association. Ibrutinib
was associated to low risk of AIHA development in registrative trials in CLL
Vaccines
Vaccines 0.8/100.000 person-years AIHA was the rarest autoimmune complication in a population study
Solid cancers
Thymoma;Ovarian/Prostate 1.29–30% autoimmune
phenomena
Thymoma, prostate and ovarian carcinomas have the highest association with
autoimmunity
AIHA, autoimmune hemolytic anemia; wAIHA, warm; cAIHA, cold; ES, Evans syndrome; ITP, immune thrombocytopenia; DAT, direct antiglobulin test; CLL, chronic lymphocytic leukemia;
ALPS, autoimmune lymphoproliferative syndrome; CVID, common variable immunodeficiency; SLE, Systemic lupus erythematosus; IBDs, inflammatory bowel syndromes.
(LT-α) may represent a risk factor for primary or secondary
AIHA development (4).
Various infections have been associated with an increased
incidence of AIHA, particularly Parvovirus B19 (associated
with DAT positive hemolysis in up to 20% of cases and
hepatotropic virus, mostly HCV and possibly related to
interferon therapy (11). Moreover, cold agglutinin AIHA occurs
in up to 3% of patients with infectious mononucleosis and
Mycoplasma pneumoniae infection (7, 11). Finally, paroxysmal
cold hemoglobinuria is almost invariably preceded by an
infection, including syphilis and virus, particularly in children
(7, 11). In addition there is a long list of drugs that have
been proven or highly suspected to induce AIHA, including
historical ones (α-methyldopa, procainamide, penicillins,
cephalosporins, diclofenac, ibuprofen, thiazides, quinine,
quinidine, metformin) and more recent molecules (cladribine,
fludarabine, lenalidomide, oxaliplatin, teniposide, pentostatin)
(7, 11). Concerning new small molecules (ibrutinib, venetoclax,
and idelalisib) few case reports of treatment-emergent AIHAs
have been published (4).
COMPREHENSIVE DIAGNOSTIC
APPROACH AND NEW DIAGNOSTIC
TOOLS
Given the several associated conditions, an accurate
diagnostic approach to AIHA is fundamental for a
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FIGURE 1 | Diagnostic algorithm of autoimmune haemolytic anemia (AIHA). DAT, direct antiglobulin test or Coombs test; MS-DAT, mitogen-stimulated DAT; CAD, cold
agglutinin disease; CT, computed tomography; G6PD, glucose-6-phosphate dehydrogenase deficiency; PKD, pyruvate kinase deficiency; EMA-binding,
eosin-5′-maleimide-binding test.
comprehensive risk assessment and a proper therapy
(Figure 1). Medical history and baseline evaluation is
still fundamental to assess drug assumption, infections,
signs of acute or chronic hemolysis, and bone marrow
compensation (reticulocytes).
The Standard DAT and More Sensitive
Techniques
As mentioned earlier, the DAT with monospecific antisera
(anti-IgG, anti- IgA, anti-IgM, anti C) is the cornerstone of
diagnosis, and allows a proper distinction of the various AIHA
forms, that have different responses to therapy and prognosis
(23). A diagnostic challenge that may take advantage of new
diagnostic tools is represented by DAT-negative AIHA, usually
5–10% of all forms. In these cases, excluding other common
causes of hemolysis and pursuing the clinical suspicion of
AIHA, it is recommended to ask for second-level tests in
a reference center. The DAT negativity due to low-affinity
antibodies may be overcome by low ionic strength solutions
(LISS) or cold washings. The small amounts of RBC-bound
antibodies (below the threshold of the test) may take advantage
of more sensitive techniques, such as microcolumn and solid-
phase antiglobulin tests. In fact, DAT tube effectively diagnoses
AIHA when at least 500 molecules of autoantibodies are
bound to RBCs, whereas microcolumn and solid phase require
∼200–300 molecules per single RBC to yield a positive
result. Consistently, DAT tube is the most specific but least
sensitive test, whereas microcolumn and solid phase methods
show reduced specificity but increased sensitivity (7, 24, 25).
Smaller amounts of autoantibodies can be detected by new,
even more sensitive techniques, such as flow cytometry (able
to detect about 30–40 antibody molecules per RBC), the
enzyme-linked and radiolabeled tests, or themitogen-stimulated-
DAT (able to amplify the autoimmune reaction in culture)
(23, 24). Of particular importance is the identification of
atypical AIHAs due to warm IgM that are potent activators of
complement and often detach from the RBC during washing
procedures, causing detrimental delay in diagnosis and therapy.
In these cases the DDAT (Dual Direct Antiglobulin Test) may
allow the diagnosis of these rare forms, usually severe and
potentially lethal (26). In addition, as complement activation is
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recognized as negative prognostic factor, evaluation of baseline
values of C3 and C4 fractions, would help completing the
diagnostic workup. Notwithstanding extensive evaluation, a
fraction of AIHA remains DAT-negative: in these cases the
diagnosis is made after the exclusion of the many hemolytic
disorders (congenital hemolytic anemias, paroxysmal nocturnal
hemoglobinuria, thrombotic microangiopathies, mechanical and
toxic noxae) and on the basis of an ex-adiuvantibus therapy
with steroids.
Causes of Falsely Positive DAT
The DAT may be positive due to the presence of alloantibodies
in recently transfused patients, in delayed hemolytic transfusion
reactions, and in the hemolytic disease of the newborn (23).
The coexistence of auto- and alloantibodies has been reported
in about 30% of AIHA patients, and their presence is often
masked by autoantibodies, possibly causing severe hemolytic
reactions in case of RBC transfusion. In complex cases
the distinction between allo- and autoantibody is advisable
by immunoabsorbance techniques and by extended RBC
genotyping (7, 24). It is worth reminding that daratumumab,
the anti-CD38 antibody for the treatment of multiple myeloma,
may give false DAT positivity. CD38 is also expressed on red-
cell membranes, resulting in panreactive agglutination in the test
used for antibody screening and cross-matching. Severalmethods
have been proposed to overcome this interference, including
pretreatment of red cells with dithiothreitol, use of antiidiotypic
antibodies against daratumumab, supplementation of soluble
CD38 to bind daratumumab in patient serum, use of red cells
from newborns as test cells, and use of F(ab′)2 fragments of
daratumumab by digestion with pepsin (27).
Bone Marrow Evaluation and Exclusion of
Secondary AIHA Forms
Among “new” diagnostic approaches to AIHA there is
the increasingly recommended (and performed) bone
marrow evaluation (morphology, cytometry, cytogenetics
and biopsy). Bone marrow evaluation may in fact give
important information on adequate erythroid compensation,
underlying lymphoproliferative disorder, and evidence of
TABLE 3 | Target therapies in autoimmune hemolytic anemia (AIHA).
Drug Mechanism Setting Route of administration Efficacy
B-cell directed monoclonal antibodies
Rituximab Anti-CD20 wAIHA/CAD IV 70–80%/50–60%
Rituximab Anti-CD20 wAIHA/CAD SC 100%
R-Fludarabine Anti-CD20 + purine analog CAD IV 76%
R-CTX-Dex Anti-CD20 + alkylator WAIHA IV 97%
R-Bendamustine Anti -CD20 + alkylator CAD IV 71%
Ofatumumab Anti-CD20 Secondary AIHA IV Case report
Alemtuzumab Anti-CD52 Secondary AIHA SC Case reports
Daratumumab Anti-CD38 Secondary AIHA IV Case reports
B-cell receptor inhibitors
Ibrutinib BTKi Secondary AIHA Oral Case reports
Parsaclisib PI3Ki Primary wAIHA/CAD Oral Not available
Venetoclax Bcl2 Secondary AIHA Oral Case reports
Proteasome inhibitor
Bortezomib Proteasome inhibitor CAD/Secondary AIHA IV Case reports
Bortezomib Proteasome inhibitor CAD IV 31.6%
Complement inhibitors
Eculizumab C5i CAD/Mixed AIHA IV Case reports
Sutimlimab Anti-C1s MoAb CAD IV 50%
APL-2 C3/C3bi CAD/wAIHA SC 50/40%
T-cell directed therapies
Soluble IL-2 T-reg stimulation wAIHA SC Not available
Sirolimus mTORi Evans’/Secondary AIHA Oral 80%
Mycophenolate Mofetil Purine synthesis inhibitor wAIHA/CAD/Secondary AIHA/Evans’ Oral 81–100%
IgG mediated phagocytosis inhibitors
Fostamatinib Syki wAIHA Oral 44%
SYNT001 FcRn MoAb wAIHA IV Not available
M281 FcRn MoAb wAIHA IV Not available
CTX, cyclophosphamide; BTKi, Bruton tyrosine kinase inhibitor; Bcl2, B-cell lymphoma 2; δPI3Ki, phosphatidylinositol-4,5-bisphosphate 3-kinase delta type inhibitor; MoAb, monoclonal
antibody; mTORi, mammalian Target Of Rapamycin inhibitor; Syki, Spleen tyrosine kinase; FcRn, neonatal crystallizable fragment receptor.
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an early/subclinical or therapy-related myelodysplasia or
bone marrow failure. These features may help in harnessing
therapy, avoiding further detrimental immunesuppression,
or selecting immunosupprors among the new targeted
therapies, based on the type of bone marrow lymphocyte
infiltrate (T or B). Moreover, the determination of endogenous
EPO levels may indicate this treatment, which has recently
shown effective particularly in relapsed/refractory and heavily
treated subjects (7, 28). To properly identify secondary
forms imaging and serologic investigation is fundamental
(Figure 1). It is advised to test for anti-phospholipid antibodies
(cardiolipin, beta-2, and lupus-like anticoagulant), given the
known thrombotic diathesis of acute/severe AIHAs, and thus
advising thromboprophylaxis. Finally, molecular analysis and
next generation sequencing would help confirming associated
conditions (primary immunodeficiencies, lymphoproliferative
disorders, myelodysplastic syndromes, other coexisting
congenital anemias) again harnessing therapy.
NEW TREATMENTS FOR AIHA
The availability of several new treatments has undoubtedly
boosted the therapeutic possibilities for patients, but at the
same time has increased the number of heavily treated,
relapsed/refractory cases. The immune-mediated pathogenic
mechanisms in AIHA are different and may differently act
at various degrees during the various phases of the disease.
Therefore, the challenge for the future will be the selection and
timing of administration of the several drugs available or under
development. Firstly, distinction between wAIHA and CAD is
pivotal, as therapy in quite different: the former usually respond
to steroids, whereas the latter requires high and unacceptable
doses. Splenectomy, although progressively abandoned and
moved to third or further lines, is still a valid option for wAIHA;
on the contrary it is ineffective and contraindicated in CAD,
where RBC destruction occurs mainly in the liver and lymphoid
organs. Likewise, it is poorly effective and discouraged in AIHA
FIGURE 2 | Transition from chronic/relapsing autoimmune hemolytic anemia (AIHA) to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and
bone marrow failure (BMF). Various immune effectors such as macrophages, antigen presenting cells (APC), T helper cells and B lymphocytes are involved into the
immune attack, which is firstly directed against peripheral erythrocytes, but may persist and involve bone marrow precursors, possibly leading to ICUS/IDUS or BMF
syndromes over time.
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secondary to immunodeficiencies, autoimmune diseases, and
lymphoproliferative disorders. Several target therapies are now
in the clinical use or under development in AIHA (Table 3)
(7, 9). Rituximab is becoming the preferred second-line for
wAIHA and is recommended as first line in CAD. In the former,
low-doses may be equally effective as standard ones, whereas
in CAD the standard schedule is more effective. The drug is
successfully administered in primary and secondary cases, alone
or associated with chemotherapy (bendamustine, fludarabine,
or other) in AIHAs secondary to lymphoproliferative diseases
(6, 29, 30). The clinical challenges are wAIHAs relapsed after
rituximab and unfit/refusing splenectomy, and CAD relapsed
after rituximab monotherapy and unfit for rituximab-combined
chemotherapy. In this setting, treatment selection would be
ideally driven by disease-related risk factors, and/or associated
conditions, as well as patient general comorbidities. Among
monoclonal antibodies, ofatumumab (anti-CD20), alemtuzumab
(anti-CD52), and daratumumab (anti-CD38) have shown
promising results in case reports, mainly secondary AIHAs.
Likewise, the orally administered B-cell receptor inhibitors
ibrutinib and venetoclax seem particularly effective in secondary
AIHAs, and the proteasome inhibitor bortezomib in 1/3 of
refractory CADs (9). A further B-cell receptor target therapy
is the PI3K inhibitor parsaclisib, which is under investigation
in both wAIHA and CAD with very promising results. An
interesting new approach for CAD is blocking complement
activation, either at the C5 level (eculizumab) or more efficiently
at the C3 (APL-2) or C1s level (sutimlimab), the latter with
about 50% responses (31). Other drugs are directed at cellular
immunity and cytokines, such as subcutaneous low-dose IL-2
and sirolimus (inhibitor of the serine treonine kinase mTOR).
Targeting IgG driven extravascular hemolysis by inhibiting the
spleen tyrosine kinase (Syk) is also an attractive approach
in wAIHA (for example fostamatinib). Finally, inhibition of
the neonatal crystallizable fragment receptor (FcRn) is a new
interesting approach: these drugs avoid protection of circulating
IgG, including pathogenic autoantibodies, from catabolism and
thus regulate innate and adaptive responses initiated by IgG
immune complexes (9).
It is worth commenting that several trials with these new drugs
are ongoing or being planned. In order to achieve meaningful
endpoints it will be essential to properly select patients, bringing
into consideration the number of previous treatments and related
complications, associated conditions, intrinsic AIHA-risk factors,
and type and degree of the immunologic dysregulation. This
would provide the basis of a risk-adapted therapy in AIHA, as
it is now advised for malignant hematologic conditions.
THE TRANSITION FROM
CHRONIC/RELAPSING AIHA TO
IDIOPATHIC CYTOPENIAS/DYSPLASIAS
OF UNCERTAIN SIGNIFICANCE
(ICUS/IDUS)
Several lines of evidence support the existence of a relationship
between MDS and autoimmunity, including their epidemiologic
association, the existence of common immune-mediated
physiopathologic mechanisms, and the response to similar
immunosuppressive therapies. This relationship may be
hypothesized also with the recently-identified conditions
ICUS and IDUS, which are defined by unexplained cytopenia
(hemoglobin <10 g/dL; platelet count <100 × 109/L; absolute
neutrophil count<1.8 × 109/L) and/or dysplasia in <10% of
bone marrow lineages (32, 33). More recently another category
has been proposed, the clonal cytopenias of undetermined
significance (CCUS), where both unexplained cytopenias and
clonal mutation are found, without fulfilling WHO criteria
for MDS (34). Of note, about 10% of the general population
aged over 70 years carries mutations in genes associated
with myeloid neoplasms, usually single mutations at a low
variant allele frequency, whose pathophysiologic role is still
unknown. These cytopenias may be considered milder MDS
forms that may evolve, after a variable period, in overt MDS
or other bone marrow failure syndromes. In this view, we
described the presence of anti-erythroblast antibodies in a case
of erythroblastic synartesis, a rare disease with an autoimmune
pathogenesis against erythroid precursors (35). Moreover, we
also described two cases of AIHA and Evan’s syndrome with
anti-erythroblast antibodies, which showed a clear-cut bone
marrow erythrocyte precursor hyperplasia at diagnosis, but
evolved into IDUS and AA after several years (33). In this
setting it is tempting to speculate that refractory/relapsing
AIHAs lose their predominant “peripheral” pattern over time,
and shift toward a “central” autoimmunity (Figure 2), leading
to a refractory anemia. Additional factors, like accumulating
somatic mutations, increased apoptosis, overinflammatory
response (inflammaging), unfavorable bone marrow cytokine
microenvironment, and breakdown of DNA-repairing tools
(telomere shortening) are likely to play a role and need to be
addressed in large prospective studies. The increasing availability
of NGS panels will also help in defining the genetic background
of the immunologic dysregulation, both in terms of inability to
clear pathogens/external triggers (chronic infection), or failure
to tolerate autoantiges (chronic autoimmune stimulation).
This would be of great importance to selectively modulate
(potentiate, down-regulate, or re-direct) the innate and adaptive
immune response and to avoid an excessively toxic approach
to autoimmunity.
AIHAs ASSOCIATED WITH TRANSPLANT
Organs and tissues transplants represent a challenging event for
the recipient immune system and may evoke an “immunologic
storm” resulting in either transplant rejection and/or devastating
immune reactions. A particular mild picture is the passenger
lymphocyte syndrome due to donor viable, immunocompetent
lymphocytes present within the graft that can produce antibodies
against donor RBCs. The syndrome involves mainly group O
donors, though few cases have been described in AB recipients
with non-AB donors. The risk of hemolysis is proportional
to the burden of transplanted lymphocytes and ranges from
9 to 70% (kidney < liver < heart-lung transplants) (11, 36).
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Onset is between 3 and 24 days post-transplant and hemolysis
is generally transient, since the lymphocytes transferred with
the donor organ do not engraft. An emerging and more
severe clinical entity is AIHA after hematopoietic stem cells
transplant (HSCT). In this setting, autoantibodies are produced
by the donor immune system against antigens on erythrocytes
produced by the graft itself, and the clinical picture is generally
severe (10). Several factors are implicated: the disease itself,
the conditioning therapy preceding transplant, the subsequent
immunosuppressive treatments, and the occurrence of HSCT
complications such as viral infections reactivation. Moreover,
the unfavorable immunologic microenvironment may lead to
graft failure (as observed in transplanted patients with aplastic
anemia), and graft immunocompetence may in turn induce graft
vs. host disease (GVHD), further complicating the clinical course.
Data from the literature report that immune hemolysis may
complicate up to 2–4% of HSCTs after a median of 3–10 months.
Both warm and cold forms are described, the former developing
between 6 and 18 months, vs. 2–8 months for the latter. Risk
factors for AIHA post HSCT are summarized in Table 4 and
include use of unrelated donor and HLA-mismatch, occurrence
of GVHD, use of cord blood, age < 15 years, CMV reactivation,
alemtuzumab use, and non-malignant condition pre-HSCT (10).
Mortality may be quite high and increases with infections (37).
Therapy of Post-Transplant AIHA
Table 4 recapitulates current and novel therapies that have
been used in AIHA post-HSCT. It is evident that the total
number of patients reported in the various studies is small,
and case reports and series carry the bias of describing good
outcomes only. However, first-line steroids seem to work
less than in primary AIHA, being effective in about 20%
of cases only. Moreover, frontline rituximab appears much
more effective than in second line (89 vs. 52% responses),
and most Authors suggest its early use, particularly in severe
cases. Splenectomy is effective but its use is limited to selected
cases given the high surgical, infectious, and thrombotic risk.
Regarding novel targeted therapies, alemtuzumab, bortezomib,
sirolimus, eculizumab, daratumumab, and abatacept have all
been used in selected cases, as 3rd or further line, with
heterogeneous outcomes. Finally, the passenger lymphocyte
syndrome may occur also in this setting and is favored
by: use of cyclosporine alone for GVHD prophylaxis, use
of peripheral blood rather than bone marrow as source
TABLE 4 | Risk factors and therapies for post-allogenic hematopoietic stem cell transplant (allo-HSCT) AIHA.
Risk factor Estimated risk 95% confidence
interval
P-value
Risk factors associated with AIHA development post-allo-HSCT
Recipient Age < 15 years n.a. n.a. 0.005
Disease features Nonmalignant diagnosis pre-HSCT 3.5 (Hazard risk)* 1.1–10.9 0.031
Donor Unrelated donor 1.45 (Relative risk) 1.05–1.99 0.02
Unrelated donor 5.28 (Hazard risk) 1.22–22.9 0.026
HLA mismatch donor n.a. n.a. 0.005
Source of stem cells Cord blood use n.a. n.a. 0.005
Conditioning Alemtuzumab use 2.5 (Hazard risk)* 1.1–5.7 0.028
Allo-HSCT complications Chronic GVHD 12.17 (Relative risk) 96–1.54 0.018
CMV reactivation 3.4 (Hazard risk)* 1.2–9.6 0.02
Drug Dose N of patients ORR (range) N of line
Therapy of AIHA post-allo-HSCT
Wait & See – 6 83% –
Steroids 1–2 mg/Kg day 125 20% (10–50) 1st line
IVIG 2 g/Kg × 2 days 51 12% (10–50) 1st line
Splenectomy – 18 38% (0–100) 2nd line
PEX – 10 10 (0–14) >2nd line
Rituximab 375 mg/sm/week × 4 weeks 18
125
89% (75–100%)
52% (36–100)
1st line
2nd line
Alemtuzumab 15 mg/day × 3/wk 2 50% (0–100) >2nd line
Bortezomib 1,3 mg/mq 19 63% (25–100) >2nd line
Sirolimus 3 mg/sm D1–1 mg/sm day 6 100% >2nd line
Eculizumab 900mg 3 33% (0–50) >2nd line
Daratumumab 16 mg/Kg/week 3 100% >2nd line
Abatacept 10 mg/Kg day 3 100% >2nd line
n.a. not available. *refers to all the autoimmune complications; PEX, plasma exchange.
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of the graft, use of reduced-intensity conditioning, use of
a non-genotypically HLA-matched donor, and use of a
female donor. Umbilical cord blood as source for stem
cells appears protective. Careful transfusion procedures are
warranted in transplanted patients, particularly in mismatched
cases (10, 36, 38).
AIHAS ASSOCIATED WITH NEW
BIOLOGICAL ANTI-CANCER THERAPIES
A fascinating field is that of anti-tumor immunotherapy,
based on the understanding that tumor cells activate immune
checkpoints such as molecular programmed death receptor-1
(PD-1) and cytotoxic T lymphocyte-associated antigen 4
(CTLA-4) signaling pathways to inhibit T lymphocyte activation
and thus escape from immune surveillance, known as “immune
brake.” Checkpoint inhibitors (CPIs) reactivate T lymphocytes
to recognize cancer cells by blocking CTLA-4 or PD-1, and
are therefore effective in numerous types of cancer. However,
immune-related adverse effects have also been reported (39,
40) and hematologic ones are rare but potentially fatal. Most
of them are monolineage cytopenia, or bilineage cytopenia,
whilst acquired hemophilia A, eosinophilia, large granular
lymphocytosis, and hemophagocytic lymphohistiocytosis are
rare (41). A meta-analysis of 9,324 patients indicated that
the incidence of anemia, neutropenia, and thrombocytopenia
was 9.8, 0.94, and 2.8%, respectively (41). AIHA is the most
commonly reported hematologic adverse event, with many case
reports of fulminant course (40). A recent revision of the
database of the Food and Drug Administration revealed a
total of 68 cases: men to women ratio was similar, and the
underlying diseases were mainly melanoma (41%), non-small
cell lung cancer (NSCLC, 26%), and others including kidney
cancer, Hodgkin’s lymphoma or skin cancers. The reported cases
were mostly from North America (49%) and Europe (34%),
with a few from Asia (10%) and Australia (7%). Forty-three
cases developed after nivolumab, 13 with pembrolizumab, 7
with ipilimumab, and 5 with atezolizumab, and 16% of cases
had received two CPIs. The median time to AIHA onset was
50 days, four patients had concurrent thrombocytopenia, other
four endocrine abnormalities (thyroiditis, adrenal insufficiency
or hypophysitis), and three gastrointestinal adverse events (colitis
or hepatitis). Most cases were IgG positive warm AIHA, whilst
CADs were rarer. All episodes were severe, with 80% of cases
developing grade 3–4 transfusion-dependent anemia, and the
risk appeared higher with PD-1 or PD-L1 targeting agents
(0.15–0.25%) than with CTLA-4 inhibitors (0.06%). Mortality
was as high as 17%, mainly due to multi-organ failure and
delayed diagnosis (42). In another recent analysis of 14 cases
who developed AIHA after CPIs, median time to AIHA was
55 days (IQR 22–110 days). Compared to primary AIHA, these
cases showed a higher proportion of DAT negativity (38%) and
of severe anemia (median Hb 6.3 g/dL (IQR, 6.1–8.0 g/dL).
Finally, 50% of cases relapsed after first line and 14% became
chronic (43). Regarding therapy, prednisone 1.5 mg−2 mg/kg
per day along with CPIs discontinuation is recommended,
and evidences for the need of early rituximab or further
immunosuppressive agents are lacking. The rechallenge of CPIs
after AIHA has improved or is stable remains inconclusive. A
patient with Hodgkin’s lymphoma who developed nivolumab
associated AIHA, that recovered after steroids and was later
re-challenged with nivolumab without AIHA recurrence, has
been described (44).
CONCLUSIONS
Nowadays the pathogenic and therapeutic landscape of AIHA
is rapidly changing for several reasons. First, numerous
AIHA-associated conditions have been identified, such as
autoimmune diseases, immunodeficiencies, and tumors, which
may have additional immune-mediated pathogenic mechanisms
compared to primary disease, and deserve a specific therapeutic
approach. In this view, the increasing use of molecular testing
has disclosed several underlying conditions, questioning the
distinction between primary and secondary forms. Second, the
development of new drugs has offered additional therapeutic
opportunities to “cure” the disease, but at the same time has
increased the number of relapsed/refractory cases. Moreover,
the future availability of even more target therapies will further
puzzle the treatment algorithm of the disease. Third, there is
increasing awareness of various pathogenic mechanisms that
may differently act during the disease course, ranging from
a predominant “peripheral” autoimmunity against erythrocytes
to a “central” attack against erythroid precursors, possibly
preceding a myelodysplastic or aplastic evolution. These findings
have further therapeutic implications, suggesting to avoid heavy
immunosuppression in favor of immunomodulating/stimulating
agents. Finally, there is increasing emergence of complex and
severe entities, particularly AIHA developing after HSCT and
AIHA associated with novel anti-cancer drugs such as checkpoint
inhibitors, which represent a clinical challenge for complications
and fatal outcome. Diagnosis of DAT-negative AIHAs and
evaluation of disease-related risk factors for relapse andmortality
have improved, but are still an unmet need. The assessment
of disease-related risk factor would be pivotal to design good
clinical trials and to give hints for a risk-adapted therapy
of AIHAs.
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